tradingkey.logo

Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026

ReutersNov 25, 2025 4:46 PM

- Silexion Therapeutics Corp SLXN.O:

  • SILEXION THERAPEUTICS SUCCESSFULLY COMPLETES TOXICOLOGY STUDIES FOR SIL204, NEXT-GENERATION RNA SILENCING THERAPY, AHEAD OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER

  • SILEXION THERAPEUTICS CORP - PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER SET FOR Q2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI